PisitPitukcheewanontMD
Pediatric Endocrinology • Los Angeles, CAAssistant Professor, Pediatrics, USC School of Medicine
Are you Dr. Pitukcheewanont?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 27 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
4650 W Sunset Blvd
Los Angeles, CA 90027Phone+1 323-669-4606Fax+1 323-664-0337
Summary
- Dr. Pisit Pitukcheewanont, MD is a pediatric endocrinologist in Los Angeles, California. He is currently licensed to practice medicine in California, North Carolina, and Utah. He is affiliated with Children's Hospital Los Angeles and is an Assistant Professor at USC School of Medicine.
Education & Training
University of TennesseeResidency, Pediatrics, 1997 - 1997- University of TennesseeFellowship, Pediatric Endocrinology, 1994 - 1996
Chiang Mai University Faculty of MedicineClass of 1987
Certifications & Licensure
UT State Medical License 1900 - Present
CA State Medical License 1998 - 2026
NC State Medical License 1997 - 2003
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- The Effects of Vitamin D on Glycemic Control and Proinflammatory Markers in Adolescents With T1DM Start of enrollment: 2012 Oct 01
Publications & Presentations
PubMed
- Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period.Leanne M Ward, Wolfgang Högler, Francis H Glorieux, Anthony A Portale, Michael P Whyte
JBMR Plus. 2024-01-01 - 5 citationsBurosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level.Erik A Imel, Francis H Glorieux, Michael P Whyte, Anthony A Portale, Craig F Munns
The Journal of Clinical Endocrinology and Metabolism. 2023-10-18 - A Novel De Novo Frameshift Pathogenic Variant in the FAM111B Resulting in Progressive Osseous Heteroplasia Phenotype.Anna Ryabets-Lienhard, Panadeekarn Panjawatanan, Kyle Vogt, Jianling Ji, Senta Georgia
Calcified Tissue International. 2023-04-01
Press Mentions
- Lumos Pharma, Inc. (LUMO) CEO Richard Hawkins on Q1 2022 Results - Earnings Call TranscriptMay 11th, 2022
